King Luther Capital Management Corp Has $192.27 Million Holdings in Abbott Laboratories $ABT

King Luther Capital Management Corp lifted its position in shares of Abbott Laboratories (NYSE:ABT) by 0.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,435,459 shares of the healthcare product maker’s stock after buying an additional 6,696 shares during the quarter. King Luther Capital Management Corp owned about 0.08% of Abbott Laboratories worth $192,265,000 at the end of the most recent reporting period.

A number of other institutional investors have also bought and sold shares of ABT. Brighton Jones LLC raised its position in shares of Abbott Laboratories by 10.1% during the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock worth $5,850,000 after purchasing an additional 4,755 shares during the period. Sivia Capital Partners LLC lifted its stake in shares of Abbott Laboratories by 3.5% in the second quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock valued at $648,000 after buying an additional 162 shares in the last quarter. United Bank grew its holdings in shares of Abbott Laboratories by 7.4% during the second quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock valued at $3,945,000 after buying an additional 2,001 shares during the last quarter. Cullen Frost Bankers Inc. increased its position in shares of Abbott Laboratories by 1.1% during the second quarter. Cullen Frost Bankers Inc. now owns 171,265 shares of the healthcare product maker’s stock worth $23,294,000 after acquiring an additional 1,818 shares in the last quarter. Finally, Retirement Planning Group LLC boosted its stake in Abbott Laboratories by 3.3% during the 2nd quarter. Retirement Planning Group LLC now owns 3,441 shares of the healthcare product maker’s stock valued at $468,000 after purchasing an additional 109 shares during the last quarter. Institutional investors own 75.18% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. Freedom Capital upgraded shares of Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 29th. Evercore cut their target price on shares of Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Argus decreased their price objective on Abbott Laboratories from $150.00 to $140.00 in a research note on Tuesday, January 27th. Barclays reduced their price target on shares of Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating for the company in a research report on Monday, February 2nd. Finally, BTIG Research cut their target price on shares of Abbott Laboratories from $145.00 to $140.00 and set a “buy” rating for the company in a research report on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $137.05.

Abbott Laboratories Trading Up 0.9%

Shares of ABT stock opened at $113.32 on Thursday. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.70 and a quick ratio of 1.24. The business has a 50-day moving average of $118.94 and a 200 day moving average of $126.10. The stock has a market capitalization of $197.05 billion, a PE ratio of 30.46, a P/E/G ratio of 1.79 and a beta of 0.75. Abbott Laboratories has a 1-year low of $105.27 and a 1-year high of $141.23.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting analysts’ consensus estimates of $1.50. The company had revenue of $11.46 billion during the quarter, compared to analyst estimates of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.94%. The firm’s revenue was up 4.4% compared to the same quarter last year. During the same period in the prior year, the business posted $1.34 EPS. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, sell-side analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, February 13th. Stockholders of record on Thursday, January 15th were paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 2.2%. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.59. The ex-dividend date of this dividend was Thursday, January 15th. Abbott Laboratories’s payout ratio is presently 67.74%.

Insider Buying and Selling

In related news, Director Daniel J. Starks acquired 10,000 shares of the firm’s stock in a transaction on Wednesday, February 4th. The stock was acquired at an average cost of $108.73 per share, for a total transaction of $1,087,300.00. Following the acquisition, the director owned 6,738,817 shares of the company’s stock, valued at $732,711,572.41. This trade represents a 0.15% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. 0.46% of the stock is owned by insiders.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.